How Mounjaro Actually Works: The Science Behind the Injection

Step 1, the injection triggers two hormone-receptor systems at once

Each weekly dose of tirzepatide binds to the receptors for two naturally occurring gut hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both are released in the gut after eating. GLP-1 slows gastric emptying, reduces appetite signals in the brain and helps regulate blood sugar. GIP works partly through fat tissue and appears to amplify the appetite-suppressing effect of GLP-1 rather than simply duplicating it.

The practical result is that within hours of injecting, the stomach empties more slowly. Food stays there longer, which prolongs the physical sense of fullness. Separately, signals to the brain's appetite centres shift, hunger becomes less insistent, and the reward-pull of high-calorie food tends to diminish. Our page on what Mounjaro actually does to the body covers those downstream effects in more detail.

A common misconception is that the injection somehow dissolves or directly burns fat. It does not. It changes the hormonal environment that governs how hungry you feel and how much you eat. Weight loss follows from eating less, the medicine adjusts the biology that makes eating less difficult. If you want to understand the fat-metabolism side more closely, there is more on whether Mounjaro burns fat and what the evidence actually shows.

Step 2, the starter dose settles your system before the work begins

Treatment opens at 2.5 mg, a dose chosen for tolerability rather than maximum effect. Its job is to give the gut time to adjust to slowed gastric emptying before the prescriber considers moving upward. Nausea and digestive discomfort (the most common early side effects) are typically most noticeable at the start of each new dose level and tend to settle over days to a couple of weeks, as described in the NHS patient information on tirzepatide.

From 2.5 mg the prescriber titrates upward in four-week steps through 5, 7.5, 10, 12.5 and 15 mg, depending on tolerability and response. The 15 mg dose is not always reached, some people find a lower dose provides sufficient effect with fewer side effects, and the prescriber makes that call based on clinical review. No patient decides their own titration schedule; at nume every repeat order is reviewed by a GPhC-registered prescriber before dispatch.

The mechanism of tirzepatide is worth reading alongside this if you want a more technical account of how the molecule itself behaves at receptor level.

Step 3, sustained weekly dosing shifts appetite set-points over months

The acute effects after each injection accumulate into longer-term changes in appetite and food preferences. Many people report that the mental noise around food (persistent thoughts about eating, the pull of habitual snacking) becomes quieter over weeks. This is consistent with what researchers observed in the SURMOUNT trial programme, where the largest weight reductions typically emerged by weeks 36 to 72, not in the first month. Weight loss with tirzepatide is gradual and sustained, not rapid and dramatic.

NICE reviewed the evidence and recommended tirzepatide in December 2024 (NICE technology appraisal TA1026) for eligible adults with a BMI of 35 or above and at least one weight-related condition, with lower thresholds applying for some ethnic backgrounds under UK guidance. Private treatment through a regulated pharmacy like nume follows the same licensed eligibility criteria (BMI 30 or above, or 27 or above with a qualifying weight-related condition) assessed individually by a prescriber. A BMI figure alone does not guarantee approval.

For a broader look at the clinical evidence and whether the real-world data backs up the trial figures, does Mounjaro really work addresses that question directly.

What this means for the people using it

Understanding the mechanism matters because it shapes reasonable expectations. Mounjaro is not a substitute for eating or activity, it works alongside a reduced-calorie diet and increased physical activity, which is a condition of the licence. What it changes is the internal experience of trying to eat less: hunger is reduced, satiety comes earlier, and the effort required to maintain a calorie deficit is lower for most people.

Side effects are real. The most common are gastrointestinal: nausea, loose stools, constipation, reflux and burping. These are predictable given how the medicine works, slowing gastric emptying affects the whole digestive system. For most people they are manageable and time-limited. Anyone experiencing severe, persistent abdominal pain that radiates to the back should seek urgent medical attention, given the known association between GLP-1 medicines and acute pancreatitis.

Mounjaro is a Black Triangle (▼) medicine, meaning the MHRA continues to monitor it actively. If you notice a side effect, you can report it at the MHRA Yellow Card scheme. If you are curious about how the cost of private treatment is structured, what determines the price of Mounjaro in the UK covers that without the marketing noise. And if you have questions about interactions (antacids come up often) there is practical information on taking Gaviscon alongside Mounjaro.